TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03578757

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 21-day residential program
Description: Both groups will benefit of a 21-day residential program at the thermal spa resort combining corrections of eating disorders (and a negative energy balance of 500 kcal/day), physical activity (2h30 per day, minimum), thermal spa treatment (2h per day, minimum), and health education (1h30 per day, minimum: cooking, nutrition and physical activity classes...). Physical activity will be diverse (endurance, strength, circuit training) and personalized to the target of each participant.~The intervention group will benefit from psychological interventions based on validated approaches of stress (3 x 1h30 per week). Participants will attend psychological sessions by group of less than 10 individuals. Individual meeting with the psychologist will occur at least twice: at the beginning of the residential program and at the end.~After the spa residential program, participants will undergo a one-year at-home follow-up.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 21-day residential program
Description: Both groups will benefit of a 21-day residential program at the thermal spa resort combining corrections of eating disorders (and a negative energy balance of 500 kcal/day), physical activity (2h30 per day, minimum), thermal spa treatment (2h per day, minimum), and health education (1h30 per day, minimum: cooking, nutrition and physical activity classes...). Physical activity will be diverse (endurance, strength, circuit training) and personalized to the target of each participant.~The intervention group will benefit from psychological interventions based on validated approaches of stress (3 x 1h30 per week). Participants will attend psychological sessions by group of less than 10 individuals. Individual meeting with the psychologist will occur at least twice: at the beginning of the residential program and at the end.~After the spa residential program, participants will undergo a one-year at-home follow-up.
Study: NCT00096083

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: isolated perfusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: melphalan
Study: NCT02291536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tetrahydrocannabinol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cannabidiol

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT00470847

Intervention type: DRUG
Group type: OTHER
Intervention: Lapatinib
Description: Orally twice daily

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Whole Brain Radiation
Description: 15 treatments over a period of 3 weeks

Intervention type: DRUG
Group type: OTHER
Intervention: Herceptin
Description: Herceptin 4mg/kg loading dose then 2 mg/kg IV once weekly, then once every three weeks after cycle 3.
Study: NCT03456440

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: MRI scan of the patients liver with DWI and acquisition of ADC value.

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: MRI scan of the patients liver with DWI and acquisition of ADC value.
Study: NCT01986140

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PAXMAN Orbis Scalp Cooler
Description: Treatment with Orbis scalp cooling cap

Intervention type: OTHER
Group type: OTHER
Intervention: Control No treatment
Description: No treatment to prevent hair loss
Study: NCT02519556

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 sachet, once a day for 6 months. Dilute one sachet in 100ml of water and take it in every morning.
Study: NCT02116387

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Physical Therapy
Description: Patients randomized to this arm will participate in a classic physical therapy program (15 weeks, a total of 15 sessions).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: I-Moove Physical Therapy
Description: Patients randomized to this arm will participate in a physical therapy program using the I-Moove device (15 weeks, a total of 15 sessions).
Study: NCT03985579

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiology taping application
Description: Application of elastic cotton strip with an acrylic adhesive that is used with the intent of treating pain and disability from athletic injuries and a variety of other physical disorders
Study: NCT04338529

Intervention type: DRUG
Intervention: Binosto 70Mg Effervescent Tablet
Description: As discussed in group descriptions

Intervention type: DRUG
Intervention: Binosto 70Mg Effervescent Tablet
Description: As discussed in group descriptions
Study: NCT03625921

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Powered device with physical therapy
Description: Subjects will be fit with a powered prosthesis (Ottobock emPOWER) and enrolled in a device-specific physical therapy (PT) program.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Powered device with standard of practice
Description: Subjects will be fit with a powered prosthesis (Ottobock emPOWER) and enrolled in the current standard of practice training, which includes basic device education and prosthetic training.
Study: NCT01723774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD0332991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD0332991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD0332991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery (standard of care)
Description: -Breast and axillary lymph node surgery
Study: NCT02105701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir + Elbasvir
Description: FDC tablet containing grazoprevir 100 mg and elbasvir 50 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 200 mg capsule
Study: NCT01723774

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery (standard of care)
Description: -Breast and axillary lymph node surgery
Study: NCT02172053

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Compensatory Workplace Exercise (CWE) - Comparative Group
Description: The comparative group will receive warming up and stretching and light resisted exercise with elastic bands. The exercise will realize three times per week, 20 minutes for day in total 60 minutes per week. With warming up for 5 minutes and 15 minutes of the specific training . The exercise will realize in 3 series with 10 repetitions and rest 30 seconds between series.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individual Resistance Exercise (IRE) - Intervention Group
Description: Intervention group will receive warming up and stretching, and a specific resistance training with increase progress load. The exercise will realize three times per week, 20 minutes for day in total 60 minutes per week. With warming up and stretching for 5 minutes and 15 minutes of the specific training. The exercise will realize in 3 series with 10 repetitions and rest 30 seconds between series.
Study: NCT03506061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trikafta
Description: Participants will take Trikafta which is a combination tablet comprised of 100 milligrams (mg) of elexacaftor, 50 mg of tezacaftor and 75 mg of ivacaftor (2 tablets taken in the morning), and 150 mg of ivacaftor taken in the evening.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trikafta
Description: Participants will take Trikafta which is a combination tablet comprised of 100 milligrams (mg) of elexacaftor, 50 mg of tezacaftor and 75 mg of ivacaftor (2 tablets taken in the morning), and 150 mg of ivacaftor taken in the evening.
Study: NCT02314234

Intervention type: DRUG
Intervention: sugammadex (Bridion)
Description: single dose of sugammadex at skin incision
Study: NCT03576222

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PICO DRESSING
Description: USE PICO DRESSING ON SURGICAL INCISION AFTER ABDOMINAL WALL REPAIR IN THE SURGICAL ROOM

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: MEPORE dressing
Description: MEPORE dressing
Study: NCT02830841

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: remote ischemic preconditioning(RIPC)
Description: After anesthesia induction, donors or recipients will be treated with automated blood pressure cuffs on their upper arms to receive RIPC by cuff inflation (to 15mmHg above systolic pressure) for 5 minutes and left inflated for 5 minutes. The cuff will then be deflated to 0 mm Hg and left uninflated for 5 minutes. This cycle will be performed 3 times in total.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham RIPC
Description: Only blood pressure cuff will be placed to the patient, but no inflation or deflation will be performed.
Study: NCT02350673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Participants will receive atezolizumab IV infusion at doses of 800 mg q2w or 1200 mg q3w.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Participants will receive atezolizumab IV infusion at doses of 800 mg q2w or 1200 mg q3w.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cergutuzumab Amunaleukin
Description: Participants will receive cergutuzumab amunaleukin IV infusion at escalated doses and at different dosing schedules in Part I and at MTD (or recommended dose) in Part II.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cergutuzumab Amunaleukin
Description: Participants will receive cergutuzumab amunaleukin IV infusion at escalated doses and at different dosing schedules in Part I and at MTD (or recommended dose) in Part II.
Study: NCT02105701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 200 mg capsule
Study: NCT01489605

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GlideScope Groove
Description: Patients will be intubated using the GlideScope Groove device. (Verathon)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control: Standard GlideScope
Description: Patients will be intubated using the standard GlideScope. (Verathon)
Study: NCT03025776

Intervention type: BEHAVIORAL
Intervention: Reaching
Description: sitting reaching under various task conditions (size, speed, location)

Intervention type: BEHAVIORAL
Intervention: Reaching
Description: sitting reaching under various task conditions (size, speed, location)

Intervention type: BEHAVIORAL
Intervention: Kinematic collection while reaching
Description: sitting reaching under various task conditions (size, speed, location), told how many \& which hand to use, kinematic data collected
Study: NCT01952691

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: kinesiotaping
Description: correction method was used to align hallux.
Study: NCT02509260

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prevena wound management system
Description: Patients will have the Prevena wound management system applied post-operatively.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard wound dressings
Description: Control patients with standard wound dressings will have gauze and tape dressings applied
Study: NCT00107016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001, Letrozole 2.5mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole 2.5mg
Study: NCT01000116

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fibrin glue
Description: Tissucol 2 ml

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tacks
Description: Protacks
Study: NCT01878617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: ROA: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: ROA: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: ROA: Orally (PO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: ROA: Orally (PO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: ROA: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: ROA: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: ROA: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: ROA: IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Training
Study: NCT01723774

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery (standard of care)
Description: -Breast and axillary lymph node surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor biopsy
Study: NCT01878617

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurocognitive Remediation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurocognitive Remediation
Study: NCT01518179

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Made-to-Measure Compression Gloves
Description: Made-to-Measure Compression Gloves in addition to routine follow up and treatment.

Intervention type: OTHER
Group type: OTHER
Intervention: Routine follow up and treatment
Description: Control
Study: NCT01878617

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurocognitive Remediation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurocognitive Remediation
Study: NCT04228731

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Outpatient
Description: Patients in the outpatient group will be discharged from the hospital the same day of surgery following a total knee arthroplasty

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inpatient
Description: Patients in the inpatient group will be discharged from the hospital the following day after a total knee arthroplasty
Study: NCT01723774

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor biopsy
Study: NCT04421001

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: I-port use
Description: patient will use I-port device fo 2 months

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: I-port use
Description: patient will use I-port device fo 2 months
Study: NCT03660449

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Moderately hypofractionated conformal radiation combined With S-1
Description: All patients will receive two cycles of S-1 (40mg/㎡, BID, po) on D1-14, D22-35, combined with thoracic radiotherapy of 60 Gy/24 fractions for GTV and 40 Gy/16 fractions for CTV.
Study: NCT01755403

Intervention type: DRUG
Group type: OTHER
Intervention: Benznidazole
Study: NCT00002759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Study: NCT01878617

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurocognitive Remediation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurocognitive Remediation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurocognitive Remediation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurocognitive Remediation
Study: NCT05432362

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aronia Juice
Description: The intervention is based an the additional consumption of 200 ml natural juice a day for a period of six weeks. The participants are asked to drink the natural and commercially available juice in addition to their regular diet. Further, they are asked not to change their diets and lifestyle behaviour during the intervention.
Study: NCT00002759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phenobarbital
Study: NCT04279587

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Residential camp
Description: Intensive education at a residential camp.
Study: NCT02262663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilaprisan (BAY1002670)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilaprisan (BAY1002670)
Study: NCT05432362

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aronia Juice
Description: The intervention is based an the additional consumption of 200 ml natural juice a day for a period of six weeks. The participants are asked to drink the natural and commercially available juice in addition to their regular diet. Further, they are asked not to change their diets and lifestyle behaviour during the intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aronia Juice
Description: The intervention is based an the additional consumption of 200 ml natural juice a day for a period of six weeks. The participants are asked to drink the natural and commercially available juice in addition to their regular diet. Further, they are asked not to change their diets and lifestyle behaviour during the intervention.
Study: NCT02262663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilaprisan (BAY1002670)
Study: NCT05432362

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A beverage is prepared according to a known recipe. It contains macro- and micronutrients in comparable amounts like the aronia juice. It is completely polyphenol free.
Study: NCT03989284

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community-based depression interventions
Description: We conducted three types of community-based depression interventions such as peer counseling, social engagement, and combination.
Study: NCT05432362

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A beverage is prepared according to a known recipe. It contains macro- and micronutrients in comparable amounts like the aronia juice. It is completely polyphenol free.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A beverage is prepared according to a known recipe. It contains macro- and micronutrients in comparable amounts like the aronia juice. It is completely polyphenol free.
Study: NCT00229151

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep deprivation and sleep phase advancement
Description: Total sleep deprivation from 0800 to 1700 next day, and three day sleep phase advancement following sleep deprivation.
Study: NCT03989284

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community-based depression interventions
Description: We conducted three types of community-based depression interventions such as peer counseling, social engagement, and combination.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community-based depression interventions
Description: We conducted three types of community-based depression interventions such as peer counseling, social engagement, and combination.
Study: NCT00229151

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual treatment
Description: Treatment as usual in the psychiatric ward. Patients in this group will be offered treatment with sleep deprivation and sleep phase advancement after five weeks if they still meet inclusion criteria
Study: NCT04576624

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention
Description: A combined approach of a lifestyle structuring intervention to improve the general health and quality of life of persons with cognitive impairments. The investigators propose to combine a multi-modal cognitive intervention and lifestyle redesign approach to improve the cognitive health of older persons with cognitive impairments.
Study: NCT01903590

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TVT surgery TOT surgery
Study: NCT04576624

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: social activity
Description: 24 social gathering events
Study: NCT02715973

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional Supplement
Description: Energy dense supplement appox. 2 kcal/mL, prepared from locally available, affordable, socially acceptable food items - milk, sugar, edible coconut oil, egg and custard powder as base) in addition to standard nutritional counseling by a trained dietician as per the recommended daily allowance according to gender and age.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard Nutritional Treatment
Description: Standard nutritional counseling by a trained dietician as per the recommended daily allowance according to gender and age
Study: NCT03964116

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaires set all 3 months
Description: This longitudinal study based upon repeated and multicentric measurement will recruit AYA with cancer in care Units dedicated to them or not. Measures will be quantitative, and repeated every 3 months by questionnaires, as well as qualitative (social network questionnaire, psychological research interview) for teenagers declaring a negative event or a death event during treatments.~Those patients presenting a high depression score will be contacted by a research psychologist for semi-directed interview.
Study: NCT03346044

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Carpentier-Edwards SAV bioprostheses
Description: Performance of these bioprostheses

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medtronic Mosaic bioprostheses
Study: NCT04524169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymosin Alpha1
Description: Thymosin Alpha 1 will be subcutaneous injected to the participants twice per week for 4 weeks.
Study: NCT01903590

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TVT surgery TOT surgery
Study: NCT02939079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod
Description: Produced by Osveh ® Pharm Company in Iran

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fingolimod
Description: Produced by Osveh ® Pharm Company in Iran

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish Oil
Description: produced by Zahravi ® Pharm Company in Iran

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for Fish Oil)
Description: placebo capsules to mimic Fish Oil 1 g capsules